


Cardiovascular Drugs Market Industry Analysis Growth Report Forecast By 2023 to 2033

Cardiovascular Drugs Market was valued at USD 169.92 Bn in 2023 and is projected to reach USD 263.88 Bn by 2033, growing at a CAGR of 4.50% from 2023 to 2033.

NEW YORK CITY, NEW YORK, UNITED STATES, January 16, 2023 /EINPresswire.com/ -- <u>Cardiovascular drugs</u> are an essential part of modern medicine, used to treat and prevent heart and circulatory system diseases. People with conditions like high blood pressure, coronary artery disease, heart failure, and stroke all rely on these medications to maintain their



health. Cardiovascular drugs include angiotensin-converting enzyme (ACE) inhibitors, betablockers, calcium channel blockers, diuretics (water pills), nitrates, and statins.

These drugs work by helping the body regulate its own cardiovascular functions. ACE inhibitors reduce inflammation in the arteries and relax the muscles of the walls of arteries so that blood can flow more easily. Beta-blockers reduce nerve impulses to the heart and allow it to beat slower and with less force.

To get a detailed analysis of other segments, Request For Sample Report: <u>https://market.us/report/cardiovascular-drugs-market/request-sample/</u>

MARKET DRIVERS

Global Market will be driven by increased awareness and innovation in new drugs

Global market growth for cardiovascular drugs is being driven by increased awareness and product launches. Herapeutics for cardiovascular treatment may use multiple types of medication. A number key market leaders have introduced many advanced drugs that address the various treatment needs for cardiovascular diseases. Eliquis (apixaban), which is a heart drug, was introduced by Bristol-Myers Squibb Company and Pfizer Inc. The product has had the greatest sales and demonstrated greater risk reductions than other drugs in the global market.

Global Market Driven by Increasing Demand for Highly Effective Drugs

Other critical factors are the global high prevalence of CVD and the demand for more effective therapies. Since their initial introduction, cardiovascular therepeutics are experiencing major RED innovations. Many new therapeutics have been successfully launched on the global markets. There are many major players in the cardiovascular market, and the growing influence of cheaper generics. This may make the market overcrowded. However, CVD is a serious condition that can be fatal and increasing numbers of patients make it more difficult to treat. This has created a significant unmet market need and is expected to be one of the key drivers in the global marketplace.

Restrains:

The market has suffered from the high cost of using cardiovascular drugs. The market's growth has been hindered by the strict guidelines and norms set forth by the government regarding the use of cardio drugs. Sales and demand have been hindered by the numerous side effects and complications associated with cardiovascular drugs. The demand for cardiovascular drugs has declined due to increasing health awareness. The pandemic has led to people taking better care of themselves and fewer people needing emergency cardiovascular drugs. Multiple factors prove to be the main limiting factor for the growth in the cardiovascular drug market.

BUY THE LATEST VERSION OF THIS REPORT https://market.us/purchase-report/?report_id=19993

Key Market Segments:

Туре

High Blood Pressure Hyperlipemia Coronary Artery Disease Peripheral Artery Disease

Application

Hospital Pharmacy Retail Pharmacy Line Medicine Bureau

Key Market Players included in the report:

AstraZeneca Pfizer Novartis Bristol-Myers Squibb Bayer Sanofi Boehringer Ingelheim GmbH F. Hoffmann-La Roche Abbott Laboratories Gilead Sciences Johnson & Johnson Astellas Pharma Eli Lilly and

Recent Development

Amgen released positive data from Phase 2 OCEAN (a)-DOSE clinical trial. This study evaluated olpasiran, formerly AMG 890, in 281 adults with Lipoprotein (a) levels above 150 nmol/L, and evidence of atherosclerotic cardio disease (ASCVD) Olpasiran, a small interferingRNA that lowers the body's production apolipoprotein (a key component in Lp(a), has been linked to an increased risk for cardiovascular events.

Empagliflozin (Jardiance), which is approved by the Food and Drug Administration (FDA) for adults with heart failure (HF), was expanded to include all ejection fractions. The August 2021 approval of the medication was made to reduce the risk for cardiovascular death and HF hospitalization among adults with HF (HFrEF) with reduced ejection fraction.

October 2019- FDA approved the addition of a new disease indication to prevent the occurrence VTE among acutely sick patients. These patients were found to be at risk of developing thromboembolic complications. However, bleeding was not an issue with rivaroxaban (a Janssen Pharmaceutical product).

In January 2019- Natco Pharma which is an Indian company disclosed the introduction of valsartan-sacubitril, which is a cardiovascular drug used in the management of congestive heart failure. The patent is held by Novartis AG in India under the name Vymada for valsartan-sacubitril.

Blackstone's Life Sciences and Novartis AG revealed the creation of Anthos Therapeutics, a company that develops cardiovascular drugs.

We have many reasons to recommend us:

- Market.us cover more than 15 major industries, segmented into more than 90 sectors.

- More than 120 countries

- More than 100 paid data sources were mined for investigation.

- Ask our research experts any questions you may have before or after you purchase your report.

- Develop an overview of the current Water Meter landscape in key markets

- Learn how regulatory or legal changes will affect the market

- Identify market prospects

Trending Reports:

Home Textile Market Size is Expected to Reach Around USD 135.6 Billion by 2025 | CAGR 5.25% <u>https://www.linkedin.com/pulse/home-textile-market-size-expected-reach-around-usd-1356-david-miller/</u>

Oschool Furniture market Size Research and Analysis | Forecast 2022-2027 https://www.linkedin.com/pulse/school-furniture-market-size-research-analysis-forecast-davidmiller/

OWine/Beverage Cooler market [+PESTLE Analysis] | Highlights Analysis till 2031 https://www.linkedin.com/pulse/winebeverage-cooler-market-pestle-analysis-highlights-davidmiller/

eReader Focus To Gain Maximum ROI [PDF] <u>https://www.linkedin.com/pulse/ereader-focus-gain-maximum-roi-pdf-david-miller/</u>

Smart Waste Management market <u>https://www.linkedin.com/pulse/smart-waste-management-market-david-miller/</u>

Breast Pads market [+How Big Is] | Value Projected to Expand by 2022-2031 <u>https://www.linkedin.com/pulse/breast-pads-market-how-big-value-projected-expand-2022-2031-miller/</u>

Peanut Butter Market size USD5.80 Billion in 2021 is expected to grow at a 7.2% CAGR <u>https://www.linkedin.com/pulse/peanut-butter-market-size-usd580-billion-2021-expected-david-miller/</u>

Cloud Robotics market Share | Sales and Growth Rate, Assessment to 2031 <u>https://www.linkedin.com/pulse/cloud-robotics-market-share-sales-growth-rate-2031-david-miller/</u> Dountain Bike market Share | New Technology and Industry Outlook 2022-2031 <u>https://www.linkedin.com/pulse/mountain-bike-market-share-new-technology-industry-outlook-miller/</u>

eDiscovery Market Size, Share, Industry Forecast by 2022-2032 <u>https://www.linkedin.com/pulse/ediscovery-market-size-share-industry-forecast-2022-2032-</u> <u>david-miller/</u>

Frequently Asked Question

What is the size of the cardiovascular drug market today?

What is the CAGR of the global market for cardiovascular drugs?

Who are the major players in the cardiovascular drug market?

Which factors are driving the cardiovascular drug market?

Which region will dominate the global market for cardiovascular drugs?

About Market.us

Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets.

Taj Prudour Pvt Lmt +1 8574450045 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/611545296

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.